-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Ultragenyx Pharmaceutical, Lowers Price Target to $70

Benzinga·12/30/2025 17:56:40
语音播报
Leerink Partners analyst Joseph Schwartz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Outperform and lowers the price target from $80 to $70.